Here are relevant reports on : ovarian-cancer-drugs-market
-
Tissue Diagnostics Market by Product (Consumables [Antibodies, Kits, Reagents, Probes], Instruments [Systems, Scanner], Software, Services), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Forecast to 2030
The global Tissue Diagnostics market, valued at US$6.19 billion in 2024, stood at US$6.74 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$10.86 billion by the end of the period. The market growth is driven by the rising incidence of cancer and the growing demand for digital pathology, which are fueling the need for more accurate and high-throughput tissue-based diagnostics.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Stomach Cancer Treatment Market by Treatment, Type (Chemotherapy, Immunotherapy), Disease Indication (Gastric Cancer), Route of Administration, Drug Class (PD-1/PD-L1 inhibitors, HER2 antagonists), Distribution Channel - Global Forecast to 2027
The global stomach cancer treatment market is projected to reach USD 8 billion by 2027 from USD 4 Billion in 2022, at a CAGR of 14% during the forecast period
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Endoscopic Submucosal Dissection/ESD Market by Product (Gastroscopes & Endoscopes, Injection Agent, Tissue Retractor), Indication (Stomach Cancer, Colon Cancer), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center) - Global Forecast to 2030
The global endoscopic submucosal dissection market, valued at US$0.46 billion in 2024, stood at US$0.50 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$0.75 billion by the end of the period. The increasing adoption of endoscopic submucosal dissection (ESD) in Western countries is becoming a significant growth driver for the global ESD market.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Forecast to 2024
The Cancer Registry Software Market is projected to reach USD 91 million by 2024, at a CAGR of 10.4%. Factors such as the increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs, and the growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market. However, factors such as privacy and data security-related concerns are expected to restrain the growth of this market to a certain extent.Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US).
- Published: March 2019
- Price: $ 11000
- TOC Available:
-
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
The global cancer immunotherapy market size is projected to grow at a CAGR of 14.0%. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market.
- Published: September 2016
- Price: $ 4950
- TOC Available:
-
Fiber Food Ingredients Market, By Type Soluble Fiber, Insoluble Fiber, Resistant Fibres, Others) By Function (Cancer
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Global Colorectal Cancer Market (2010-2015)
2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Ophthalmology Drugs & Devices Market (Contact Lens, Optical Coherence Tomography (OCT) Scanner, IOL, Dry Eye, AMD, Glaucoma & Phacoemulsification) – Competitive Landscape & Global Forecasts To 2017
The global ophthalmology market witnessed a dip during the economic downturn in 2008 and 2009; however, it is poised to grow at a stable rate mainly due to an increasing aging population, large pool of patients with eye diseases, changing demographics and geographical trends, and increased focus on combination therapies of drugs. Moreover, incidences of glaucoma and cataract are increasing every year.
- Published: August 2012
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
